EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Day

December 4, 2010

Second Annual Gastric Cancer Fund Gala

On Saturday, December 4, 2010, the 2nd Annual Gastric Cancer Fund Gala took place at the Peninsula Golf and Country Club in...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

6 days ago

Amgen announced it has halted a late-stage trial of bemarituzumab, a drug targeting FGFR2b overexpression that it was testing along with immunotherapy in gastric cancer patients. The company cited inadequate efficacy as the reason for stopping the trial. “We remain committed to creating and developing medicines for challenging cancers where unmet need is significant, as for patients with gastric cancer,” said Jay Bradner, M.D., Amgen’s executive vice president of R&D, during an investor call. Via FierceBiotech ... See MoreSee Less

Amgen halts gastric cancer trial after antibody 'did not meet our standard' of efficacy, exec says

www.fiercebiotech.com

Following a middling phase 3 readout for gastric cancer candidate bemarituzumab, Amgen has now

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

7 days ago

UCLA Health’s Dr. Zev Wainberg discusses notable gastric cancer research presented at the ESMO - European Society for Medical Oncology conference. ... See MoreSee Less

Dr Wainberg on Treatment Updates in Gastric Cancer and Biliary Tract Cancer | OncLive

www.onclive.com

Zev A. Wainberg, MD, MSc, highlighted notable research in gastric cancer and cholangiocarcinoma presented during the 2025 ESMO GI Congress.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

In a phase 3 study from BeOne Medicines, Tevimbra combined with chemotherapy showed promising results as a first-line treatment for advanced gastric cancer. Patients were followed for three years, and the combination treatment showed durable and improved efficacy over chemotherapy alone. ... See MoreSee Less

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up - PubMed

pubmed.ncbi.nlm.nih.gov

ClinicalTrials.gov Identifier: NCT03777657.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

Akeso, Inc. 康方生物（9926.hk） PD-1/CTLA-4 bispecific antibody, cadonilimab, combined with chemotherapy showed long-term survival benefits in a gastric cancer trial, the company announced at the ESMO - European Society for Medical Oncology Congress. #ESMO25 ... See MoreSee Less

Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025

www.prnewswire.com

/PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

3 weeks ago

An experimental anti-HER2 bispecific antibody anbenitamab (KN026) from Alphamab Oncology, in combination with chemotherapy, had an objective response rate of 55.8% in patients with HER2-positive gastric cancer, the company announced at the ESMO - European Society for Medical Oncology Congress. The drug, now in phase 2/3 trials in gastric cancer in China, was granted Orphan Drug status by the FDA. #ESMO25 ... See MoreSee Less

www.prnewswire.com

404

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

Please join with us to fuel the next wave of progress.

Your support honors the memories of those we have lost and creates much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Please join with us to fuel the next wave of progress. Support our 2025 Fundraising Campaign.

Your support honors the memories of those we have lost and creates much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Powering progress to defeat stomach cancer.

Powering progress to defeat stomach cancer.

MORE INFO DONATE DONATE MORE INFO

X